We are live on ! Find out more
BLACR

Bellevue Life Sciences Acquisition Corp. Rights
BLACR

Delisted

BLACR was delisted on the 14th of February, 2025.

Back to rankings

28 hedge funds and large institutions have $550K invested in Bellevue Life Sciences Acquisition Corp. Rights in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less capital invested

Capital invested by funds: $562K → $550K (-$11.9K)

7% less funds holding

Funds holding: 30 → 28 (-2)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
28
Holders Change
-2
Holders Change %
-6.67%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$9.72K
2
FTUS
Flow Traders U.S.
New York
+$237

Top Sellers

Rank Fund Capital Flow
1
EAM
Exos Asset Management
New York
-$18.1K
2
CS
Clear Street
New York
-$653
3
BI
Bulldog Investors
New Jersey
-$554
4
Citadel Advisors
Citadel Advisors
Florida
-$40
5
UBS Group
UBS Group
Switzerland
-$2
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$87.2K – – –
PC
2
Periscope Capital
Ontario, Canada
$57.2K – – –
PAMP
3
Polar Asset Management Partners
Ontario, Canada
$39.3K – – –
BFM
4
Boothbay Fund Management
New York
$36.4K – – –
CAC
5
Cowen and Company
New York
$35.3K +$9.72K +73,397 +29%
ASM
6
ATW SPAC Management
New York
$34K – – –
JP Morgan Chase
7
JP Morgan Chase
New York
$31.3K – – –
SCM
8
Saba Capital Management
New York
$29.3K – – –
SCM
9
Shaolin Capital Management
Florida
$28.8K – – –
RCM
10
Rivernorth Capital Management
Florida
$26.1K – – –
CS
11
Clear Street
New York
$20.3K -$653 -4,926 -3%
Walleye Capital
12
Walleye Capital
New York
$18.4K – – –
HCM
13
Heights Capital Management
California
$17.1K +$20.7K +156,176 New
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$15.6K – – –
WAM
15
Wolverine Asset Management
Illinois
$13.3K – – –
AA
16
AQR Arbitrage
Connecticut
$10.4K – – –
CC
17
Centiva Capital
New York
$10.4K – – –
Walleye Trading
18
Walleye Trading
New York
$10.3K – – –
MTCM
19
Mint Tower Capital Management
Netherlands
$8K – – –
SIA
20
Schechter Investment Advisors
Michigan
$4.74K – – –
SIA
21
SkyView Investment Advisors
New Jersey
$4K – – –
GF
22
Gabelli Funds
New York
$2.95K – – –
Citadel Advisors
23
Citadel Advisors
Florida
$2.53K -$40 -300 -1%
GCIA
24
Gabelli & Co Investment Advisers
New York
$2.27K – – –
FTUS
25
Flow Traders U.S.
New York
$2K +$237 +1,785 +12%
1
2

BLACR Hedge Fund Activity: Q3 2024 in Review

28 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q3 2024, worth a combined $550K — down 2.1% from $562K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BLACR and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.

The largest buyer was Cowen and Company, adding an estimated $9.72K. The largest seller was Exos Asset Management, exiting entirely with an estimated $18.1K sold.

  • 28 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q3 2024, down from 30 in Q2 2024.
  • Funds reported $550K of Bellevue Life Sciences Acquisition Corp. Rights stock for Q3 2024, down 2.1% quarter-over-quarter.
  • 1 fund opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q3 2024 and 2 closed out, a net change of -1 holder.
  • The largest Bellevue Life Sciences Acquisition Corp. Rights buyer in Q3 2024 was Cowen and Company, an estimated $9.72K added.
  • The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q3 2024 was Exos Asset Management, an estimated $18.1K sold.

Based on aggregated 13F filings for Q3 2024.